Privately held Thrasos Therapeutics has raised $35 million in financing from a consortium of investors to take THR-184 — its lead compound for the treatment of acute kidney injury — through to Phase II clinical proof of concept. Investors in the Montreal-based firm are: SR One, GSK Life Sciences Innovation Fund, SW Co, Advanced Technology…
Organization: Fonds de solidarite FTQ
Milestone received $13 million in equity financing
Montreal’s Milestone Pharmaceuticals Inc has completed a $13-million equity financing to further development of its flagship compound (MSP-2017) for the treatment of a cardiac arrhythmia called paroxysmal supraventricular tachycardia (PSVT). The financing was provided by Pappas Ventures, the BDC Health Venture Fund, GO Capital, Fonds de solidarite FTQ, and previous investors iNovia Healthcare and Fonds…
Applied PeR$pectives
Building with CCNB-INNOV… Relationships that go a Long Way! CCNB-INNOV, the applied research and development arm of CCNB has adapted its range of services to better meet the unique needs of the regional shipbuilding industry.
 |
Applied PeR$pectives is a new monthly blog dedicated to highlighting the innovative work being done in the college and institute community. |
|---|
Fast Policy Facts
 |
December 12, 2018: Requiem for a National Network Program
|
|---|
Research Money on Twitter
Loading tweets...